Vitality Watch

Dossier rss preclinical 10-sep-2026
Animal model, organoid, or cell-culture result — not yet human

NAD+ Metabolic Reprogramming Drives CD8+ T Cells Senescence and Exacerbates Ulcerative Colitis

Key claim: NAD+ metabolic reprogramming drives senescence of CD8+ T cells and thereby exacerbates ulcerative colitis.

Abstract

Aging Cell, Volume 25, Issue 9, September 2026.

Why this matters

NAD+ decline is heavily marketed via NR/NMN supplements as a general anti-aging lever, but this study places NAD+ metabolism upstream of a specific pathological output — CD8 T-cell senescence driving ulcerative colitis severity via mtDNA–cGAS–STING — rather than a diffuse healthspan claim. It extends the senescence/inflammaging picture into adaptive immunity and an autoimmune tissue context, and hints that NAD+ status may modulate response to conventional IBD anti-inflammatories. Preclinical mouse causality plus human correlational signal only; no NAD-repletion or senolytic trial in UC patients yet.

Source

Link

Briefing card

NAD+ Metabolic Reprogramming Drives CD8+ T Cells Senescence and Exacerbates Ulcerative Colitis
Stage: preclinical · rss · 10-sep-2026

If you take NR or NMN with active inflammatory bowel disease, note that this preclinical work suggests NAD+ metabolic shifts can push CD8+ T cells toward senescence and worsen colitis — a caution flag, not a human outcome.

NAD+ metabolic reprogramming drives senescence of CD8+ T cells and thereby exacerbates ulcerative colitis.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: url:https://onlinelibrary.wiley.com/doi/10.1111/acel.70706?af=R

build build 880 · 2bcef25 · 2026-11-18